Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

PARP-1 inhibition sensitizes temozolomide-treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity andPTENproficiency

Full text
Author(s):
Montaldi, Ana P. [1] ; Lima, Sarah C. G. [1] ; Godoy, Paulo R. D. V. [1] ; Xavier, Danilo J. [1] ; Sakamoto-Hojo, Elza T. [1, 2]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, USP, Fac Philosophy Sci & Letters Ribeirao Preto, Dept Biol, 3900 Bandeirantes Ave, BR-14040901 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, USP, Ribeirao Preto Med Sch, Dept Genet, BR-14049900 Ribeirao Preto, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: ONCOLOGY REPORTS; v. 44, n. 5, p. 2275-2287, NOV 2020.
Web of Science Citations: 0
Abstract

Information on the mechanisms that are associated with tumor resistance has the potential to provide the fundamental basis for novel therapeutic strategies. In glioblastoma (GBM), predictive biomarkers of cellular responses to temozolomide (TMZ) combined with poly-ADP-ribose polymerase inhibitor (PARPi) remain largely unidentified. In this context, the influence of MGMT (O-6-methylguanine DNA methyltransferase) and PTEN (phosphatase and tensin homologue deleted on chromosome ten) has been studied in addition to the occurrence of synthetic lethality involving PTEN and PARPi. The present study investigated whether PARP-1 inhibition by NU1025 may increase the cytotoxicity of TMZ-induced lesions in GBM cells, and whether these mechanisms can be influenced by MGMT andPTENstatus. The impact ofPTENdeficiency in repair pathways, and the effects of PARP-1 inhibition andPTENsilencing, in terms of synthetic lethality, were also assessed. NU1025 combined with TMZ effectively sensitized TMZ-resistant cells (T98GPTEN-mutated and LN18PTEN-wild-type) and TMZ-sensitive cells (U251MGPTEN-mutated), in contrast to NU1025 alone. However, the sensitizing effects were not observed in U87MG (PTEN-mutated) cells, suggesting that specific genetic alterations may influence the response to drug treatment. The sensitizing effects occurred independently of MGMT activity, which was evaluated in O6-BG-treated cells.PTENsilencing using small interfering (si)RNA did not sensitizePTEN-proficient cells to TMZ + NU1025, or NU1025 alone, indicating an absence of synthetic lethality. The responses to TMZ + NU1025 involved antiproliferative activity, G2/M arrest, double strand breaks and the induction of apoptosis. Following 20 days of recovery after three consecutive days of TMZ treatment, TMZ-resistant cells were observed. However, when TMZ was combined with NU1025, the viability of T98G and LN18 cells was extremely decreased, indicating a lethal drug combination. Therefore, independently of MGMT proficiency andPTENstatus, TMZ combined with PARPi may be a promising strategy that can be used to overcome TMZ acquired resistance in GBM cells. (AU)

FAPESP's process: 16/17862-3 - Evaluation of the influence of MGMT inhibition in the responses of glioblastoma cell lines to TMZ treatment combined to the PARP-1 inhibitor (NU1025)
Grantee:Sarah Caroline Gomes de Lima
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 13/12033-0 - "INHIBITION OF DNA REPAIR IN GLIOBLASTOMA CELL LINES TARGETING A POTENTIAL APPLICATION AS A THERAPEUTIC STRATEGY"
Grantee:Ana Paula de Lima Montaldi
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 13/09352-7 - Genomic instability and molecular signaling pathways involving DNA damage responses and DNA repair in human diseases
Grantee:Elza Tiemi Sakamoto Hojo
Support type: Regular Research Grants